Drug Approval | January 21, 2022
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
This is the company’s first partnership arrangement in China
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
Subscribe To Our Newsletter & Stay Updated
